Revvity to Acquire ACD/Labs to Expand Signals Software Capabilities

Reuters

Nov 10, 2025

Revvity to Acquire ACD/Labs to Expand Signals Software Capabilities

Revvity, Inc. has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions specializing in analytical characterization and molecular design for the pharmaceutical and material sciences sectors. The deal will expand the capabilities of Revvity Signals' software platform, integrating ACD/Labs' industry-leading tools such as the Spectrus® Platform for advanced spectral analysis and the Percepta® Platform for AI-driven molecular property prediction. By combining their technologies, the companies aim to deliver a unified SaaS environment that connects molecular design, analytical science, and manufacturing quality control, supporting scientific workflows from discovery through to manufacturing. The transaction is expected to close late in the fourth quarter of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251110692197) on November 10, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582876236"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582876236\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582876236?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582876236","market":"fut","top_or_hot":-1,"title":"Revvity to Acquire ACD/Labs to Expand Signals Software Capabilities","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Revvity to Acquire ACD/Labs to Expand Signals Software Capabilities\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Revvity, Inc. has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions specializing in analytical characterization and molecular design for the pharmaceutical and material sciences sectors. The deal will expand the capabilities of Revvity Signals' software platform, integrating ACD/Labs' industry-leading tools such as the Spectrus® Platform for advanced spectral analysis and the Percepta® Platform for AI-driven molecular property prediction. By combining their technologies, the companies aim to deliver a unified SaaS environment that connects molecular design, analytical science, and manufacturing quality control, supporting scientific workflows from discovery through to manufacturing. The transaction is expected to close late in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251110692197) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revvity to Acquire ACD/Labs to Expand Signals Software Capabilities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevvity to Acquire ACD/Labs to Expand Signals Software Capabilities\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 20:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Revvity to Acquire ACD/Labs to Expand Signals Software Capabilities\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Revvity, Inc. has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions specializing in analytical characterization and molecular design for the pharmaceutical and material sciences sectors. The deal will expand the capabilities of Revvity Signals' software platform, integrating ACD/Labs' industry-leading tools such as the Spectrus® Platform for advanced spectral analysis and the Percepta® Platform for AI-driven molecular property prediction. By combining their technologies, the companies aim to deliver a unified SaaS environment that connects molecular design, analytical science, and manufacturing quality control, supporting scientific workflows from discovery through to manufacturing. The transaction is expected to close late in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251110692197) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVTY","symbol_name":"REVVITY INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL9ZZJSJ:1","article_id":"2582876236","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582876236","pubTimestamp":1762778719,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Revvity, Inc. has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions specializing in analytical characterization and molecular design for the pharmaceutical and material sciences sectors. The deal will expand the capabilities of Revvity Signals' software platform, integrating ACD/Labs' industry-leading tools such as the Spectrus Platform for advanced spectral analysis and the Percepta Platform for AI-driven molecular property prediction. By combining their technologies, the companies aim to deliver a unified SaaS environment that connects molecular design, analytical science, and manufacturing quality control, supporting scientific workflows from discovery through to manufacturing. The transaction is expected to close late in the fourth quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVTY":"REVVITY INC","BK4121":"生命科学工具和服务","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"Revvity将收购ACD/Labs以扩展信号软件功能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVTY":0.9},"content_text":"Revvity to Acquire ACD/Labs to Expand Signals Software Capabilities\n    \n\n        Revvity, Inc. has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions specializing in analytical characterization and molecular design for the pharmaceutical and material sciences sectors. The deal will expand the capabilities of Revvity Signals' software platform, integrating ACD/Labs' industry-leading tools such as the Spectrus® Platform for advanced spectral analysis and the Percepta® Platform for AI-driven molecular property prediction. By combining their technologies, the companies aim to deliver a unified SaaS environment that connects molecular design, analytical science, and manufacturing quality control, supporting scientific workflows from discovery through to manufacturing. The transaction is expected to close late in the fourth quarter of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251110692197) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}